Exelixis (EXEL) Curent Deferred Tax Liability (2011)

Exelixis' (EXEL) quarterly Curent Deferred Tax Liability came in at $700000.0 in Q4 2011.

Exelixis (EXEL) Curent Deferred Tax Liability (2011) Analysis & Trends

Exelixis' Curent Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $700000.0 for Q4 2011.

On a quarterly basis, Curent Deferred Tax Liability changed N/A year-over-year to $700000.0 in Q4 2011; TTM through Dec 2011 was $700000.0, a N/A change from a year earlier, with the FY2011 full-year figure at $700000.0, changed N/A from the prior year.
Curent Deferred Tax Liability was little changed at $700000.0 in Q4 2011 per EXEL's latest filing.
Across five years, Curent Deferred Tax Liability topped out at $700000.0 in Q4 2011 and bottomed at $700000.0 in Q4 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Curent Deferred Tax (Qtr)
1	Oculis Holding AG	65,719.23 Bn	65,718.94 Bn	-	-
2	Nanobiotix	1,933.82 Bn	1,933.76 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-
4	BeOne Medicines	471.85 Bn	467.06 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	122.29 Bn	115.04 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	70.04 Bn	61.28 Bn	3.31 Bn	-
7	Belite Bio	62.06 Bn	62.06 Bn	-	-
8	Argenx Se	55.78 Bn	50.60 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.47 Bn	34.47 Bn	959.66 Mn	-
10	Exelixis	14.43 Bn	13.65 Bn	590.86 Mn	-

Download Data

Date	Value
Dec 31, 2011	700,000.00
Dec 31, 2011	700,000.00